Neuronox (ニューロノックス)

What is Neuronox?

Neuronox® is botulinum toxin type A complex (100 Units) manufactured by Medy-Tox Inc.

Throughout the 1980s and 1990s, Clostridium botulinum had been intensively researched by a group of scientists in Korea. In 2000, the scientists established a biotech venture named “Medy-Tox Inc.”, which specializes in botulinum and its toxins. Following much research on biological, biochemical, immunological and toxicity aspects, botulinum toxin type A has been developed as a biopharmaceutical product.

The First Choice of Botulinum Toxin Type-A Drug

For last years, many preclinical and clinical studies of Neuronox have been performed very successfully in Korea as well as other countries. Neuronox has shown excellent results in therapeutic as well as cosmetic studies. Customers and partners in more than 50 countries have been using Neuronox.

In 2004 and 2005, Neuronox has been licensed to famous pharmaceutical companies including Ranbaxy which is one of the biggest generics companies in the world. Ranbaxy will invest significant resources to make Neuronox a mega brand in India and other countries. Also, a famous Korean pharmaceutical company, CJ Corp., licensed the marketing and sales rights to launch Neuronox into the Latin and South America of more than 50 countries. All these licensing cases show the credibility of Neuronox.

Taking into account its efficacy, safety, and price compared with competitive products, Neuronox is the most welcomed choice of botulinum toxin drug for both doctors and patients in the world.

Specification

How does Neuronox work?

Neuronox blocks neuromuscular transmission binding to acceptor sites on motor nerve terminals, entering the nerve terminals, and inhibiting the release of acetylcholine.

This inhibition occurs as the neurotoxin cleaves SNAP-25, a protein integral the successful docking and release of acetylcholine from vesicles situated within nerve endings.

When injected intramuscularly at therapeutic doses, Neuronox produces partial chemical denervation of the muscle resulting in a localized reduction in muscle activity. In addition, the muscle may atrophy, axonal sprouting may occur, and extra junctional acetlcholine receptors may develop. There is evidence that reinnervation of the muscle may occur, thus slowly reversing muscle denervation produced by Neuronox.